Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.66
BDX's Cash to Debt is ranked higher than
66% of the 315 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.11 vs. BDX: 0.66 )
BDX' s 10-Year Cash to Debt Range
Min: 0.04   Max: 1.03
Current: 0.66

0.04
1.03
Equity to Asset 0.44
BDX's Equity to Asset is ranked higher than
60% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. BDX: 0.44 )
BDX' s 10-Year Equity to Asset Range
Min: 0.36   Max: 0.63
Current: 0.44

0.36
0.63
Interest Coverage 9.09
BDX's Interest Coverage is ranked higher than
61% of the 212 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.30 vs. BDX: 9.09 )
BDX' s 10-Year Interest Coverage Range
Min: 7.22   Max: 42.29
Current: 9.09

7.22
42.29
F-Score: 5
Z-Score: 4.83
M-Score: -2.99
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 15.35
BDX's Operating margin (%) is ranked higher than
86% of the 311 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.19 vs. BDX: 15.35 )
BDX' s 10-Year Operating margin (%) Range
Min: 14.62   Max: 22.75
Current: 15.35

14.62
22.75
Net-margin (%) 11.67
BDX's Net-margin (%) is ranked higher than
85% of the 311 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.12 vs. BDX: 11.67 )
BDX' s 10-Year Net-margin (%) Range
Min: 7.59   Max: 18.49
Current: 11.67

7.59
18.49
ROE (%) 19.08
BDX's ROE (%) is ranked higher than
93% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.39 vs. BDX: 19.08 )
BDX' s 10-Year ROE (%) Range
Min: 15.67   Max: 28.17
Current: 19.08

15.67
28.17
ROA (%) 8.06
BDX's ROA (%) is ranked higher than
85% of the 316 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.40 vs. BDX: 8.06 )
BDX' s 10-Year ROA (%) Range
Min: 6.66   Max: 14.79
Current: 8.06

6.66
14.79
ROC (Joel Greenblatt) (%) 25.79
BDX's ROC (Joel Greenblatt) (%) is ranked higher than
82% of the 315 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.21 vs. BDX: 25.79 )
BDX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 23.63   Max: 46.7
Current: 25.79

23.63
46.7
Revenue Growth (%) 11.60
BDX's Revenue Growth (%) is ranked higher than
87% of the 284 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.10 vs. BDX: 11.60 )
BDX' s 10-Year Revenue Growth (%) Range
Min: 4.4   Max: 11.9
Current: 11.6

4.4
11.9
EBITDA Growth (%) 2.60
BDX's EBITDA Growth (%) is ranked higher than
70% of the 240 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.10 vs. BDX: 2.60 )
BDX' s 10-Year EBITDA Growth (%) Range
Min: 2.6   Max: 15.7
Current: 2.6

2.6
15.7
EPS Growth (%) 0.20
BDX's EPS Growth (%) is ranked higher than
69% of the 244 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.60 vs. BDX: 0.20 )
BDX' s 10-Year EPS Growth (%) Range
Min: -0.6   Max: 21.9
Current: 0.2

-0.6
21.9
» BDX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

BDX Guru Trades in Q4 2013

Arnold Van Den Berg 1,815 sh (New)
Jim Simons 1,119,100 sh (+166.07%)
John Hussman 125,000 sh (+25%)
Jeremy Grantham 1,732,079 sh (+8.78%)
Bill Frels 5,188 sh (+2.98%)
Yacktman Fund 780,000 sh (unchged)
Michael Price 200,000 sh (unchged)
Jeff Auxier 44,100 sh (unchged)
Yacktman Focused Fund 670,000 sh (unchged)
Ruane Cunniff 2,272 sh (unchged)
Vanguard Health Care Fund 2,571,700 sh (unchged)
Robert Olstein 65,000 sh (unchged)
Joel Greenblatt Sold Out
Pioneer Investments 985,610 sh (-0.08%)
Donald Yacktman 1,752,710 sh (-0.35%)
Dodge & Cox 17,380 sh (-0.57%)
Manning & Napier Advisors, Inc 2,531,099 sh (-1.72%)
Richard Pzena 2,634,751 sh (-2.18%)
Mario Gabelli 597,700 sh (-3.12%)
Paul Tudor Jones 4,494 sh (-11.88%)
Chris Davis 3,635 sh (-20.98%)
Ray Dalio 4,295 sh (-47.83%)
Steven Cohen 2,571 sh (-87.92%)
» More
Q1 2014

BDX Guru Trades in Q1 2014

Steven Cohen 61,535 sh (+2293.43%)
Paul Tudor Jones 6,600 sh (+46.86%)
Jim Simons 1,342,000 sh (+19.92%)
Pioneer Investments 1,010,161 sh (+2.49%)
Chris Davis 3,635 sh (unchged)
Ruane Cunniff 2,272 sh (unchged)
Bill Frels 5,188 sh (unchged)
Vanguard Health Care Fund 2,571,700 sh (unchged)
Arnold Van Den Berg Sold Out
Jeff Auxier 43,450 sh (-1.47%)
Dodge & Cox 16,880 sh (-2.88%)
Richard Pzena 2,537,209 sh (-3.7%)
Manning & Napier Advisors, Inc 2,399,462 sh (-5.2%)
Jeremy Grantham 1,621,998 sh (-6.36%)
Mario Gabelli 550,705 sh (-7.86%)
Robert Olstein 57,000 sh (-12.31%)
Michael Price 175,000 sh (-12.5%)
Yacktman Fund 660,000 sh (-15.38%)
John Hussman 100,000 sh (-20%)
Donald Yacktman 1,300,476 sh (-25.8%)
Ray Dalio 2,995 sh (-30.27%)
Yacktman Focused Fund 450,000 sh (-32.84%)
» More
Q2 2014

BDX Guru Trades in Q2 2014

Jean-Marie Eveillard 582,656 sh (New)
Joel Greenblatt 80,303 sh (New)
John Hussman 175,000 sh (+75%)
Jim Simons 1,550,700 sh (+15.55%)
Paul Tudor Jones 6,842 sh (+3.67%)
Richard Pzena 2,600,468 sh (+2.49%)
Pioneer Investments 1,018,372 sh (+0.81%)
Donald Yacktman 1,304,228 sh (+0.29%)
Manning & Napier Advisors, Inc 2,400,462 sh (+0.04%)
Yacktman Fund 660,000 sh (unchged)
Ruane Cunniff 2,272 sh (unchged)
Yacktman Focused Fund 450,000 sh (unchged)
Chris Davis Sold Out
Ray Dalio Sold Out
Dodge & Cox 16,780 sh (-0.59%)
Mario Gabelli 544,832 sh (-1.07%)
Bill Frels 5,088 sh (-1.93%)
Robert Olstein 54,000 sh (-5.26%)
Vanguard Health Care Fund 2,393,100 sh (-6.94%)
Jeff Auxier 39,950 sh (-8.06%)
Jeremy Grantham 1,431,598 sh (-11.74%)
Michael Price 135,000 sh (-22.86%)
» More
Q3 2014

BDX Guru Trades in Q3 2014

Yacktman Fund 660,000 sh (unchged)
Yacktman Focused Fund 450,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with BDX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2014-06-30 Add 75%0.69%$111.18 - $120.33 $ 125.738%175000
Michael Price 2014-06-30 Reduce -22.86%0.57%$111.18 - $120.33 $ 125.738%135000
Jean-Marie Eveillard 2014-06-30 New Buy0.17%$111.18 - $120.33 $ 125.738%582656
Joel Greenblatt 2014-06-30 New Buy0.12%$111.18 - $120.33 $ 125.738%80303
Chris Davis 2014-06-30 Sold Out $111.18 - $120.33 $ 125.738%0
Ray Dalio 2014-06-30 Sold Out $111.18 - $120.33 $ 125.738%0
Michael Price 2014-03-31 Reduce -12.5%0.36%$105.4 - $116.81 $ 125.7312%175000
Yacktman Focused Fund 2014-03-31 Reduce -32.84%0.26%$105.4 - $116.81 $ 125.7312%450000
Donald Yacktman 2014-03-31 Reduce -25.8%0.2%$105.4 - $116.81 $ 125.7312%1300476
John Hussman 2014-03-31 Reduce -20%0.2%$105.4 - $116.81 $ 125.7312%100000
Yacktman Fund 2014-03-31 Reduce -15.38%0.12%$105.4 - $116.81 $ 125.7312%660000
Robert Olstein 2014-03-31 Reduce -12.31%0.12%$105.4 - $116.81 $ 125.7312%57000
Arnold Van Den Berg 2014-03-31 Sold Out 0.02%$105.4 - $116.81 $ 125.7312%0
Ray Dalio 2014-03-31 Reduce -30.27%$105.4 - $116.81 $ 125.7312%2995
John Hussman 2013-12-31 Add 25%0.2%$98.33 - $110.6 $ 125.7318%125000
Arnold Van Den Berg 2013-12-31 New Buy0.02%$98.33 - $110.6 $ 125.7318%1815
Joel Greenblatt 2013-12-31 Sold Out 0.01%$98.33 - $110.6 $ 125.7318%0
Ray Dalio 2013-12-31 Reduce -47.83%$98.33 - $110.6 $ 125.7318%4295
Chris Davis 2013-12-31 Reduce -20.98%$98.33 - $110.6 $ 125.7318%3635
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Becton Dickinson & Co

Weekly 52-Week Highs Highlight: SRCL, BDX, LINTB, NI
According to GuruFocus list of 52-week highs; Stericycle Inc., Becton Dickinson & Co., Liberty Interactive Corp. and NiSource Inc. have all reached their 52-week highs. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 25.50
BDX's P/E(ttm) is ranked higher than
82% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 34.70 vs. BDX: 25.50 )
BDX' s 10-Year P/E(ttm) Range
Min: 10.23   Max: 30.81
Current: 25.5

10.23
30.81
P/B 4.52
BDX's P/B is ranked higher than
52% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.99 vs. BDX: 4.52 )
BDX' s 10-Year P/B Range
Min: 2.96   Max: 4.92
Current: 4.52

2.96
4.92
P/S 2.97
BDX's P/S is ranked higher than
65% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. BDX: 2.97 )
BDX' s 10-Year P/S Range
Min: 1.99   Max: 3.54
Current: 2.97

1.99
3.54
PFCF 16.35
BDX's PFCF is ranked higher than
92% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 84.15 vs. BDX: 16.35 )
BDX' s 10-Year PFCF Range
Min: 13.37   Max: 32.56
Current: 16.35

13.37
32.56
EV-to-EBIT 19.87
BDX's EV-to-EBIT is ranked higher than
82% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.53 vs. BDX: 19.87 )
BDX' s 10-Year EV-to-EBIT Range
Min: 9.8   Max: 20.7
Current: 19.87

9.8
20.7
PEG 6.38
BDX's PEG is ranked higher than
84% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. BDX: 6.38 )
BDX' s 10-Year PEG Range
Min: 0.92   Max: 7.8
Current: 6.38

0.92
7.8
Shiller P/E 20.93
BDX's Shiller P/E is ranked higher than
91% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 224.47 vs. BDX: 20.93 )
BDX' s 10-Year Shiller P/E Range
Min: 13.74   Max: 33.31
Current: 20.93

13.74
33.31
Current Ratio 2.89
BDX's Current Ratio is ranked higher than
75% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.74 vs. BDX: 2.89 )
BDX' s 10-Year Current Ratio Range
Min: 1.17   Max: 3.54
Current: 2.89

1.17
3.54
Quick Ratio 2.15
BDX's Quick Ratio is ranked higher than
76% of the 310 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.82 vs. BDX: 2.15 )
BDX' s 10-Year Quick Ratio Range
Min: 0.7   Max: 2.76
Current: 2.15

0.7
2.76

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.73
BDX's Dividend Yield is ranked higher than
61% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.44 vs. BDX: 1.73 )
BDX' s 10-Year Dividend Yield Range
Min: 0.92   Max: 2.44
Current: 1.73

0.92
2.44
Dividend Payout 0.42
BDX's Dividend Payout is ranked higher than
78% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. BDX: 0.42 )
BDX' s 10-Year Dividend Payout Range
Min: 0.16   Max: 1.07
Current: 0.42

0.16
1.07
Dividend growth (3y) 10.20
BDX's Dividend growth (3y) is ranked higher than
80% of the 123 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.70 vs. BDX: 10.20 )
BDX' s 10-Year Dividend growth (3y) Range
Min: 2.6   Max: 29.1
Current: 10.2

2.6
29.1
Yield on cost (5-Year) 2.81
BDX's Yield on cost (5-Year) is ranked higher than
75% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. BDX: 2.81 )
BDX' s 10-Year Yield on cost (5-Year) Range
Min: 1.52   Max: 4.04
Current: 2.81

1.52
4.04
Share Buyback Rate 6.70
BDX's Share Buyback Rate is ranked higher than
96% of the 244 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.30 vs. BDX: 6.70 )
BDX' s 10-Year Share Buyback Rate Range
Min: 6.7   Max: -1.1
Current: 6.7

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 7.83
BDX's Price/Tangible Book is ranked higher than
52% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.70 vs. BDX: 7.83 )
BDX' s 10-Year Price/Tangible Book Range
Min: 3.09   Max: 14.99
Current: 7.83

3.09
14.99
Price/DCF (Projected) 1.44
BDX's Price/DCF (Projected) is ranked higher than
83% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.30 vs. BDX: 1.44 )
BDX' s 10-Year Price/DCF (Projected) Range
Min: 0.99   Max: 3.79
Current: 1.44

0.99
3.79
Price/Median PS Value 1.11
BDX's Price/Median PS Value is ranked higher than
63% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. BDX: 1.11 )
BDX' s 10-Year Price/Median PS Value Range
Min: 0.5   Max: 1.33
Current: 1.11

0.5
1.33
Price/Graham Number 2.94
BDX's Price/Graham Number is ranked higher than
75% of the 327 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.13 vs. BDX: 2.94 )
BDX' s 10-Year Price/Graham Number Range
Min: 1.63   Max: 5.25
Current: 2.94

1.63
5.25
Earnings Yield (Greenblatt) 5.00
BDX's Earnings Yield (Greenblatt) is ranked higher than
70% of the 231 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. BDX: 5.00 )
BDX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.8   Max: 10.2
Current: 5

4.8
10.2
Forward Rate of Return (Yacktman) 6.64
BDX's Forward Rate of Return (Yacktman) is ranked higher than
79% of the 274 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.38 vs. BDX: 6.64 )
BDX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 7.2   Max: 19.7
Current: 6.64

7.2
19.7

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:BOX.Germany
Becton Dickinson & Co. was incorporated under the laws of the State of New Jersey in November 1906, as successor to a New York business started in 1897. The Company is a global medical technology Company engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. Its operations consist of three worldwide business segments: BD Medical, BD Diagnostics and BD Biosciences. BD Medical produces an array of medical devices that are used in a range of healthcare settings. They include many safety-engineered injection, infusion and surgery products. BD Medical's product lines include needles, syringes and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles for the self-injection of insulin and other drugs used in the treatment of diabetes; prefill able drug delivery devices provided to pharmaceutical companies and sold to end-users as drug/device combinations; surgical blades/scalpels and regional anesthesia needles and trays; critical care monitoring devices; ophthalmic surgical instruments; and sharps disposal containers. BD Diagnostics provides products for the safe collection and transport of diagnostics specimens, as well as instrument systems and reagents to detect a range of infectious diseases, healthcare-associated infections (HAIs) and cancers. BD Diagnostics' products include integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood culturing systems; molecular testing systems for sexually transmitted diseases and HAIs; microorganism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; and plated media. BD Biosciences produces research and clinical tools that facilitate the study of cells, and the components of cells, to gain a better understanding of normal and disease processes. BD Biosciences' product lines include fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life sciences research; cell imaging systems; laboratory products for tissue culture and fluid handling; diagnostic assays; and cell culture media supplements for biopharmaceutical manufacturing. The main customers served by BD Biosciences are research and clinical laboratories; academic and government institutions; pharmaceutical and biotechnology companies; hospitals; and blood banks. The main products sold by BD outside of the U.S. are needles and syringes; insulin syringes and pen needles; diagnostic systems; BD Vacutainer (tm) brand blood collection products; BD Hypak(tm) brand prefill able syringe systems; infusion therapy products; flow cytometry instruments and reagents; and disposable laboratory products. BD has manufa
» More Articles for BDX

Headlines

Articles On GuruFocus.com
Dividend Aristocrats in Focus Part 18 of 54: Becton, Dickinson & Company Oct 14 2014 
Weekly 52-Week Highs Highlight: BDX, DUK, CFN, INFY Oct 12 2014 
Becton and Dickinson Provides Shareholders with Solid Returns Oct 03 2014 
Medtronic Inc. (MDT) Dividend Stock Analysis Sep 12 2014 
Critical Investor John Hussman's Top Five Q2 Holdings Aug 01 2014 
Top Three Holdings with Promising Outlook Jul 15 2014 
Becton, Dickinson and Co. (BDX) Dividend Stock Analysis May 30 2014 
CR Bard Focuses on Small to Medium-Sized Deals Apr 04 2014 
Weekly 52-Week Highs Highlight: SRCL, BDX, LINTB, NI Jan 20 2014 
3 Top Yielding Dividend Aristocrats with Low Dividend Payouts Oct 09 2013 

More From Other Websites
Becton, Dickinson Acquires GenCell Biosystems in Ireland Oct 14 2014
BD Acquires GenCell Biosystems Oct 13 2014
[$$] Review Oct 11 2014
[$$] Last Week Oct 11 2014
Today's Market Thorns, Roses, and All Time Highs... Oct 09 2014
Today's Market Thorns, Roses, and All Time Highs... Oct 08 2014
Medical Device ETF in Focus on Recent Merger Activity Oct 08 2014
Dollar surge puts Q4 earnings at risk and two-year stock uptrend in peril Oct 08 2014
Today's Market Thorns, Roses, and All Time Highs... Oct 07 2014
Stifel: CareFusion Corporation Deal May Have Far-Flung Effects Oct 07 2014
CareFusion & Becton, Dickinson Scale Highs on Merger Deal Oct 07 2014
[video] Becton Dickinson and CareFusion Tie-up Heralds More Sector M&A Oct 07 2014
Becton, Dickinson (BDX) Jumps: Stock Moves 7.9% Higher Oct 07 2014
Becton Dickinson upgraded by Stifel Oct 07 2014
Today's Market Thorns, Roses and All Time Highs... Oct 06 2014
Morgan Stanley: CareFusion Corporation Deal Offers 'Good, Not Great' Returns For Becton, Dickinson... Oct 06 2014
U.S. equities opened the session stronger Oct 06 2014
[video]Stock Market Today: Nasdaq, Russell Lead Losses as Chipmakers and Small-Caps Suffer Oct 06 2014
Credit analysts raise red flag on Becton merger Oct 06 2014
How Becton Dickinson's $12B Deal for CareFusion Benefits Shareholders Oct 06 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK